Baird Maintains Nuvalent(NUVL.US) With Buy Rating, Maintains Target Price $105
Jefferies Maintains Nuvalent(NUVL.US) With Buy Rating, Maintains Target Price $97
Piper Sandler Maintains Nuvalent(NUVL.US) With Buy Rating, Maintains Target Price $100
Nuvalent Price Target Maintained With a $99.00/Share by Wedbush
Nuvalent Analyst Ratings
Buy Rating Affirmed for Nuvalent: Optimistic Drug Efficacy and Financial Projections
Wedbush Maintains Nuvalent(NUVL.US) With Buy Rating, Maintains Target Price $99
LifeSci Capital Maintains Nuvalent(NUVL.US) With Buy Rating, Raises Target Price to $105
Wedbush Sticks to Its Buy Rating for Nuvalent (NUVL)
Barclays Maintains Nuvalent(NUVL.US) With Buy Rating, Maintains Target Price $100
Barclays Maintains Nuvalent(NUVL.US) With Buy Rating, Maintains Target Price $100
J.P. Morgan Maintains Nuvalent(NUVL.US) With Buy Rating, Raises Target Price to $100
Analysts Offer Insights on Healthcare Companies: Nuvalent (NUVL) and Ardelyx (ARDX)
Piper Sandler Maintains Nuvalent(NUVL.US) With Buy Rating, Raises Target Price to $100
Nuvalent Initiated at Overweight by Barclays
Nuvalent Analyst Ratings
Barclays Initiates Nuvalent(NUVL.US) With Buy Rating, Announces Target Price $100
Nuvalent (NUVL) Receives a Buy From Barclays
Analysts Offer Insights on Healthcare Companies: Xenon (XENE), Nuvalent (NUVL) and Dianthus Therapeutics (DNTH)
Buy Rating Affirmed for Nuvalent Amid Promising NVL-655 Clinical Trial Progress and Anticipated Efficacy Superiority